How we drive changeShare
Our team uses a 3-part model to ensure our research is constructively applied by the many stakeholders working in access to medicine, to limit antimicrobial resistance (AMR), and to drive up standards across the pharmaceutical industry.
Model for change
Three-part model for driving positive change:
- Build consensus on where pharmaceutical companies can and should be taking action to improve access to medicine and curb AMR. Every two years, we translate the stakeholder consensus into clear metrics for measuring company behaviour, which we publish in our methodology reports.
- Stimulate competition by identifying the best performers on access to medicine and AMR and publicly recognising companies’ positive actions. This triggers other companies to join a “race to do well” on priority health targets and topics.
- Share best practices identified through our research, in order to facilitate the wider application of best practices and the development of new approaches to long-standing barriers to access.
Direct engagement with key stakeholders in access
To turn our insights into positive change, we engage with pharmaceutical companies directly, as well as with donors, NGOs, governments and the investor community, to improve companies’ long-term thinking on access to medicine and AMR and to increase the application of best practices.
As shareholders, investors are assured a seat at the table when it comes to steering the direction of investee companies. Institutional investors use the Foundation's insights and analysis to better manage risks and opportunities for pharmaceutical companies related to access-to-medicine and antimicrobial resistance, and to inform direct engagements with investee companies. To date, over 150 investors managing assets of more than USD 25 trillion have committed to use our data and insights. Read more about our work with investors.
Our government engagement team liaises with governments, private foundations, multilateral organisations and non-governmental organisations that are actively working to improve global health and access to medicine in order to share the Foundation’s research findings and identify key opportunities for collaboration and change-making. Read more about our work with policy-makers.
With pharmaceutical companies directly
Our company engagement team spurs positive action through direct engagement with pharmaceutical companies, in the form of meetings, briefings and workshops. This includes sharing the Foundation’s research results and catalysing discussions of opportunities and best practices with companies’ leadership and access teams. Read more about our Amsterdam Sessions, which provide a forum for the people leading companies' access programmes to learn from each other about their successes and challenges.
Our work on medical oxygen
In the battle against the COVID-19 pandemic, many low- and middle-income countries are facing major medical oxygen shortages. We are working to move the medical gas industry with global health organisations, investors and policy makers to permanently close the gaps in access to this essential medical treatment.
Three research programmes
Ranks 20 of the world’s largest pharmaceutical companies based on seven areas of behaviour linked to access: strategy, governance, R&D, pricing, licensing, capacity building and donations. The Index is the most comprehensive, long-running survey of company behaviour regarding access to medicine.
The first report to independently evaluate how a cross-section of the pharmaceutical industry are taking action to bring antimicrobial resistance under control.
Standalone assessment of how vaccine companies are ensuring all children can be immunised, wherever they live. By uncovering what is working and where, the Index helps ensure vaccine markets also reach the poorest and most remote communities.
The Foundation's progress in advancing access to medicine
In 2020, the Access to Medicine Foundation commissioned an independent evaluation of the Foundation's progress in advancing access to medicine in low- and middle-income countries. The evaluation concluded that "the work of the Foundation has likely already contributed to improve access to medicine for millions of people and also produced millions in cost savings for LMICs."
For more information about the independent evaluation, please contact Damiano de Felice, Director of Strategy.